



Quality Improvement Organizations

Sharing Knowledge. Improving Health Care.
CENTERS FOR MEDICARE & MEDICAID SERVICES


Great Plains



Quality Innovation Network



**Antibiotic Stewardship:
Regulated or Voluntarily Mandated?**



“What would your children look like if they had a respiratory challenge and we could not trust or could not have an antibiotic that would be effective on it? That would be very scary.”

~Mark Gardiner, Kansas Rancher

<https://www.bovinevetonline.com/article/stewardship-and-resistance-ranchers-perspective-antibiotics>

Why?

Antibiotic resistance is among the greatest public health threats today, leading to an estimated 2 million infections and 23,000 deaths per year in the United States.

Estimated minimum number of illnesses and deaths caused annually by antibiotic resistance*:


At least  **2,049,442** illnesses,
 **23,000** deaths

**bacteria and fungus included in this report*



Community Antibiotic Prescriptions per 1,000 Population by State - 2015

At least 30% of antibiotics prescribed in doctors' offices, emergency departments and hospital clinics are unnecessary.*




Data source: IMS Health Xponent 2014

*Fleming-Dutra, K., et al. (2016). "Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011." *JAMA, the Journal of the American Medical Association* 315(17): 1864-1873



ZIP Code Level FFS Beneficiary Density for Antibiotic Prescribing Rates for Upper Respiratory Infections (URI) (10/1/16-9/30/17)




National Rate: 55.66%

Antibiotic Prescribing Rate for URI


1 Dot = 15 Beneficiaries

- | | |
|-------------------|-------------------|
| ● 0.00% - 37.36% | ● 56.59% - 60.00% |
| ● 37.37% - 44.00% | ● 60.01% - 63.64% |
| ● 44.01% - 49.06% | ● 63.65% - 67.29% |
| ● 49.07% - 53.15% | ● 67.30% - 72.73% |
| ● 53.16% - 56.58% | ● >= 72.74% |



This material was prepared by Telligen, the Quality Innovation Network National Coordinating Center, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. The contents presented do not necessarily reflect CMS policy. [11SOW-QINCC-02118-05/17/18]

Diagnoses Leading to Antibiotics — United States, 2010–11



ESTABLISHED RISKS OF ANTIBIOTIC USE



INCREASED INFECTION RISK

Even though antibiotics are used to treat infections, they can also increase the risk of some types of infections. For example, people who have recently taken an antibiotic are at more risk of diarrhea caused by bacteria while traveling (i.e., traveler's diarrhea) or are at more risk of infection during outbreaks of foodborne illness caused by bacteria. In addition, infections caused by *C. difficile* bacteria and *Candida* fungi are common when taking antibiotics.



Clostridium difficile (*C. difficile*)

Each year nearly half a million illnesses and 15,000 deaths are caused by *C. difficile* infections. People taking antibiotics are 7 to 10 times more likely to get *C. difficile* while on the drugs, or in the month after taking them, than people not taking antibiotics.¹⁻⁴



Candida

When a person's microbiome is disrupted by taking an antibiotic, there is increased risk for fungus (yeast) such as *Candida* species to grow. Common types of *Candida* infection are diaper rashes caused by yeast, vaginal yeast infections, and infections of the mouth and throat (also called thrush). In patients hospitalized for serious conditions or who have weak immune systems, *Candida* can cause severe illness, including bloodstream infections, or death.



ALLERGIC REACTIONS

Among children, antibiotics are the most common cause of emergency department visits for reactions to drugs. Most of these visits are for allergic reactions, which can range from mild rashes and itching to life-threatening swelling of the face and throat and breathing problems (called anaphylaxis).



DRUG INTERACTIONS


Antibiotics can interact with other drugs patients take. Then, those drugs, or the antibiotics, become less effective or the patient has worse side effects.



ANTIBIOTIC RESISTANCE

When a patient takes an antibiotic, the bacteria it is fighting might adapt to develop new resistance against the drug. The resistant bacteria can then cause resistant infections in that patient and/or spread to other people.

History of Antibiotics



<https://www.cdc.gov/drugresistance/about.html>

What is Antibiotic Stewardship?


- Antibiotic stewardship is the effort to:
 - Measure antibiotic prescribing
 - Improve antibiotic prescribing so that antibiotics are only prescribed and used when needed
 - Minimize misdiagnoses or delayed diagnoses leading to underuse of antibiotics
 - Ensure that the right drug, dose, and duration are selected when an antibiotic is needed



It's about patient safety and delivering high-quality healthcare.

Why the Outpatient Setting?

- High levels of antibiotic use
 - Majority of human antibiotic use occurs in outpatients
 - 30% of outpatient antibiotic prescriptions are unnecessary
 - 50% of antibiotics for acute respiratory conditions are unnecessary
- It's a matter of patient safety
 - Side effects from antibiotics lead to an estimated 143,000 emergency department visits per year
 - Antibiotic treatment is the most important risk factor for *Clostridium difficile* infection
- Inappropriate antibiotic use is primary modifiable driver of antibiotic resistance




Shehab N, et al. Clin Infect Dis 2008;47:735–43. Gonzales R et al. Clin Infect Dis 2001;33:757–62. Suda et al. J Antimicrob Chemother 2013; 68: 715–718

Fleming-Dutra KE et al. JAMA 2016;315:1864–73

https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/362374/ESPAUR_Report_2014_3_.pdf


<https://www.folkhalsomyndigheten.se/pagefiles/20281/Swedres-Svarm-2014-14027.pdf>

NHSN Reporting Required



Percent of Hospitals with Antibiotic Stewardship Programs by State, 2015*


Nationally, 48.1% of all hospitals have stewardship programs (2,199 of 4,549); the national goal is 100% of hospitals by 2020.



*A hospital stewardship program is defined as a program following all 7 of CDC's Core Elements of Hospital Antibiotic Stewardship Programs.

Source: CDC's National Healthcare Safety Network (NHSN) Survey

Percentage of U.S. Acute Care Hospitals (n=4,569) Implementing All 7 Core Elements of Hospital Antibiotic Stewardship Programs





NATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA

Vision: The United States will work domestically and internationally to prevent, detect, and control illness and death related to infections caused by antibiotic-resistant bacteria by implementing measures to mitigate the emergence and spread of antibiotic-resistance and ensuring the continued availability of therapeutics for the treatment of bacterial infections.

MARCH 2015



https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibiotic-resistant_bacteria.pdf

**Presidential Advisory Council
on Combating Antibiotic-
Resistant Bacteria (PACCARB)**Text Resize **A A A**

Share



About Us

Charter

Timeline

How We Work

Membership

Meetings

Past Meetings

Upcoming Meetings

Reports & Recommendations

Working Groups

Contact Us

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB)

The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) provides advice, information, and recommendations to the Secretary regarding programs and policies intended to support and evaluate the implementation of U.S. government activities related to combating antibiotic-resistant bacteria.

I would like info on...

- > [The September 26, 2018 Public Meeting](#)
- > [Announcing our 2018 Liaison Members](#)
- > [Call for Nominations 2018](#) - now closed

About PACCARB

Learn about why PACCARB was established and what it does.



Membership

Learn about PACCARB's voting members, organizational liaisons, ex officio members, and advisory council staff.

Meetings

Find details about upcoming PACCARB meetings and related important information.

PACCARB

Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria

Authority

Executive Order 13676, dated September 18, 2014, requires establishment of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (Advisory Council). The Advisory Group is currently operating under the authority given in Executive Order 13708, dated September 30, 2015. Activities of the Advisory Council are governed by the provisions of Public Law 92-463, as amended (5 U.S.C. App.), which sets forth standards for the formation and use of federal advisory committees.

Objectives and Scope of Activities

Executive Order 13676 directs the Secretary of Health and Human Services (Secretary) to establish the Advisory Council in consultation with the Secretaries of Defense and Agriculture. The Advisory Council will provide advice, information, and recommendations to the Secretary regarding programs and policies intended to support and evaluate the implementation of Executive Order 13676, including the National Strategy for Combating Antibiotic-Resistant Bacteria (Strategy) and the National Action Plan for Combating Antibiotic-Resistant Bacteria (Action Plan). The Advisory Council shall function solely for advisory purposes.

Description of Duties

In carrying out its mission, the Advisory Council will provide advice, information, and recommendations to the Secretary regarding programs and policies intended to:

1. Preserve the effectiveness of antibiotics by optimizing their use;
2. Advance research to develop improved methods for combating antibiotic resistance and conducting antibiotic stewardship;
3. Strengthen surveillance of antibiotic-resistant bacterial infections;
4. Prevent the transmission of antibiotic-resistant bacterial infections;
5. Advance the development of rapid point-of-care and agricultural diagnostics;
6. Further research on new treatments for bacterial infections;
7. Develop alternatives to antibiotics for agricultural purposes;
8. Maximize the dissemination of up-to-date information on the appropriate and proper use of antibiotics to the general public and human and animal healthcare providers; and

CMS Conditions of Participation

- §482.42 The hospital must provide a sanitary environment to avoid sources and transmission of infections and communicable diseases. There must be an active program for the prevention, control, and investigation of infections and communicable diseases.

National Patient Safety Goals

Goal 7:

Reduce the risk of health care-associated infections.

https://www.jointcommission.org/assets/1/6/NPSG_Chapter_HAP_Jan2018.pdf

National Patient Safety Goals

- NPSG.07.01.01: Comply with either the current Centers for Disease Control and Prevention (CDC) hand hygiene guidelines or the current World Health Organization (WHO) hand hygiene guidelines.
 - *Applies to: Ambulatory, Behavioral Health Care, Critical Access Hospital, Home Care, Hospital, Lab, Long Term Care, Office-Based Surgery*


National Patient Safety Goals

- NPSG.07.03.01: Implement evidence-based practices to prevent health care-associated infections due to multidrug-resistant organisms in acute care hospitals.
 - *Applies to: Critical Access Hospital, Hospital*
- NPSG.07.04.01: Implement evidence-based practices to prevent central line-associated bloodstream infections.
 - *Applies to: Critical Access Hospital, Hospital, Long Term Care*


National Patient Safety Goals

- NPSG.07.05.01: Implement evidence-based practices for preventing surgical site infections.
 - *Applies to: Ambulatory, Critical Access Hospital, Hospital, Office-Based Surgery*
- NPSG.07.06.01: Implement evidence-based practices to prevent indwelling catheter-associated urinary tract infections (CAUTI).
 - *Applies to: Critical Access Hospital, Hospital.* (Note: This NPSG is not applicable to pediatric populations. Research resulting in evidence-based practices was conducted with adults, and there is not consensus that these practices apply to children.)

Data Reporting Timeline



Journey to Reporting



Infection Prevention Joins the Journey

2009

Federal Omnibus bill requires state plan development

Congress allocates \$40 million to CDC for building state capacity for HAI prevention

CDC provides plan template

2011

NHSN reporting begins for HIQR with CLABSI in the ICU

2013

CDI lab-identified events, MRSA and Healthcare worker immunization added

2015

HIQR NHSN reporting expands CAUTI & CLABSI to medical, surgical and med/surg wards for FY2016 payment

2010

Kansas plan implemented

2012

HIQR NHSN reporting expands to include CAUTI in the ICU and SSI – hysterectomies and colon procedures

2014

FY2015 VBP adds CLABSI to the outcome measure domain

Pending Legislation

CMS-3295-P

Hospital and Critical Access Hospital (CAH) Changes to Promote Innovation, Flexibility, and Improvement in Patient Care CMS-3295-P

Docket Folder Summary [View all documents and comments in this Docket](#)

Docket ID: CMS-2016-0095 Agency: Centers for Medicare Medicaid Services (CMS) Parent Agency: Department of Health and Human Services (HHS)

Summary:

These proposed changes would modernize hospital and critical access hospital (CAH) requirements, improve quality of care, and support HHS and CMS priorities. Specifically, we proposed to revise the conditions of participation (CoPs) for hospitals and CAHs to address: Discriminatory behavior by healthcare providers that may create real or perceived barriers to care; Use of the term "Licensed Independent Practitioners" (LIPs) that may inadvertently exacerbate workforce shortage concerns; Requirements that do not fully conform to current standards for infection control; Requirements for antibiotic stewardship programs to help reduce inappropriate antibiotic use and antimicrobial resistance; and the use of quality reporting program data by hospital Quality Assessment and more...

RIN: 0938-AS21 Impacts and Effects: Small Entities (Business) CFR Citation: 42 CFR 482,42 CFR 485 Priority: Economically Significant

[View Less UA and Regulatory Plan Information and Docket Details](#)

UA and Regulatory Plan Information

Publication Period: Fall 2016
 Agenda Stage of Rulemaking: Long-term Action
 Major Rule: Yes
 Legal Authorities: 42 U.S.C. 1302, 42 U.S.C. 1395hh and 1395rr
 Government Levels Affected: No

Federalism Implications: No
 Unfunded Mandates: No
 Requires Regulatory Flexibility Analysis: No
 Small Entities Affected: Business
 International Impacts: No
 Included in Regulatory Plan: No

Legal Deadline

Action	Source	Description	Date
Statutory	Other	MMA section 902.	06/16/2019

Timetable

Action	Date	FR Citation
NPRM	06/16/2016	81 FR 39447
NPRM Comment Period End	08/15/2016	
Final Action	06/00/2019	

Docket Details

Related RINs: None
 Related Dockets: None
 Type: Rulemaking

www.regulations.gov/docket?D=CMS-2016-0095

Take a Tour!

Sign up for Email Alerts

201
Comments Received*

Tweet Share Email

Regulatory Timeline




Agency Contact

CDR Scott Cooper
 Senior Technical Advisor
 CMS/HHS
 scott.cooper@cms.hhs.gov
 410 786-9465

Key Investments to Combat Antibiotic Resistance

Hover over and select state for more details.



AR Solutions *In Action* FISCAL YEAR **2017**
 CDC's Investments to Combat Antibiotic Resistance Threats Nationwide

Investing to Defend the U.S. against Antibiotic Resistance

Antibiotic resistance (AR), where germs do not respond to the drugs designed to kill them, threatens us to the same extent as single infections were often fatal. CDC is committed to protecting Americans and the future of healthcare, veterinary, and agriculture industries from the threat of antibiotic resistance.

The AR Investment Map illustrates CDC's activities to meet national goals to prevent drug-resistant infections. CDC supports most of these activities through its AR Solutions Initiative, while also leveraging investments from successful programs across the agency for maximum efficiency.

CDC's AR Solutions Initiative puts state and local AR laboratory and epidemiological expertise in every state and makes investments in public health innovation to fight AR across healthcare settings, food, and communities.

Since 2016, CDC's AR Solutions Initiative has supported comprehensive AR work nationwide.

- \$144 million to 57 state and local health departments
- \$76.5 million for public health innovation
- 63 public/private institutions
- 84 applied public health research projects

DETECTION, RESPONSE & CONTAINMENT

- **Laboratory & Diagnostic:** Cold standard full capacity offered to all state and regional labs through CDC's AR Laboratory Network
- **Epidemiology Capacity for Response:** Increased capacity in state and local health departments for rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread

PREVENTION

- **Surveillance & Science:** More effective prevention of healthcare-associated infections, foodborne illness, and gonorrhea
- **Improved Antibiotic Use:** With partners, improve antibiotic use to ensure antibiotics work to protect patients from life-threatening infections or sepsis

INNOVATION

- **Insights for Practice:** With academic and healthcare partners, CDC is investing in innovations and collaborating with investigators to identify and implement new ways to prevent antibiotic-resistant infections and their spread
- **Research and Development:** Sharing isolates that inform development of new drugs and diagnostics, and making public CDC's sequencing data from AR pathogens to spur innovation in industry

These investments work toward meeting national goals to prevent drug-resistant infections as outlined in the National Action Plan for Combating Antibiotic-Resistant Infections.

See CDC's AR investments by state at www.cdc.gov/ARinvestments.

#ARinAction #ARinAction

CDC provides critical support to every state to protect Americans from antibiotic resistance.
www.cdc.gov/ARinvestments

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

This map represents CDC's largest funding categories for antibiotic resistance. It shows domestic, extramural funding that supports AR activities from multiple funding lines.

Investing to Defend the U.S. against Antibiotic Resistance

CDC is committed to protecting Americans and the future of healthcare, veterinary, and agriculture industries from the threat of antibiotic resistance. CDC supports most of these activities through its [AR Solutions Initiative](#), while also leveraging investments from successful programs across the agency for maximum efficiency.

CDC partners with health departments, academia, and the healthcare, veterinary, and agriculture industries to grow the science and implement strategies that protect Americans from antibiotic resistance.

Get Email Updates

To receive email updates about this page, enter your email address:

KANSAS

\$673,763

Funding for AR Activities
Fiscal Year 2017



FUNDING TO STATE HEALTH DEPARTMENTS



\$481,569

RAPID DETECTION & RESPONSE to emerging drug-resistant germs is critical to contain the spread of these infections.

With 2016 funding, Kansas worked with partners to increase the number of healthcare facilities reporting to National Healthcare Safety Network from 80 to 182. This data sharing increases the state's capacity to use timely and accurate data to target its HAI/AR prevention and response efforts.



\$192,194

FOOD SAFETY projects protect communities by rapidly identifying drug-resistant foodborne bacteria to stop and solve outbreaks and improve prevention.

In Fiscal Year 2018, Kansas will ramp up testing to include whole genome sequencing of all *Listeria*, *Salmonella*, *Campylobacter* and *E. coli* isolates and simultaneously monitor these isolates for resistance genes. States upload the sequence data into PulseNet for nationwide monitoring of outbreaks and trends. When outbreaks are detected, local CDC-supported epidemiologists investigate the cases to stop spread.

Antibiotic Resistance (AR) Solutions Initiative

Improve antibiotic use through antibiotic stewardship, sepsis recognition, and prevention.



Set national goals to improve antibiotic use.

» Cut inappropriate prescribing practices by 50% in doctors' office and 20% in hospitals.



Implement effective stewardship programs using CDC's Core Elements and recommendations in doctors' offices, hospitals, and nursing homes, integrated with sepsis early recognition programs.



Support collaboration to develop and evaluate stewardship activities.



Provide data about antibiotic use and trends to better understand prescribing practices. For example:

» Expand and use CDC's National Healthcare Safety Network (NHSN) data to guide improvement of antibiotic use in hospitals.

» Better understand differences in prescribing patterns in doctors' offices by states and develop strategies for improvement.



Expand State HAI/AR Prevention Programs to help implement best practices around improving antibiotic prescribing.



Support early recognition of sepsis. Heighten public awareness to prevent sepsis and its complications, and to improve antibiotic use.

Core Actions to Combat Resistance

1 PREVENTING INFECTIONS, PREVENTING THE SPREAD OF RESISTANCE



Avoiding infections in the first place reduces the amount of antibiotics that have to be used and reduces the likelihood that resistance will develop during therapy. There are many ways that drug-resistant infections can be prevented: immunization, safe food preparation, handwashing, and using antibiotics as directed and only when necessary. In addition, preventing infections also prevents the spread of resistant bacteria.

2 TRACKING



CDC gathers data on antibiotic-resistant infections, causes of infections and whether there are particular reasons (risk factors) that caused some people to get a resistant infection. With that information, experts can develop specific strategies to prevent those infections and prevent the resistant bacteria from spreading.

3

IMPROVING ANTIBIOTIC PRESCRIBING/STEWARDSHIP



Perhaps the single most important action needed to greatly slow down the development and spread of antibiotic-resistant infections is to change the way antibiotics are used. Up to half of antibiotic use in humans and much of antibiotic use in animals is unnecessary and inappropriate and makes everyone less safe. Stopping even some of the inappropriate and unnecessary use of antibiotics in people and animals would help greatly in slowing down the spread of resistant bacteria. This commitment to always use antibiotics appropriately and safely—only when they are needed to treat disease, and to choose the right antibiotics and to administer them in the right way in every case—is known as antibiotic stewardship.

4

DEVELOPING NEW DRUGS AND DIAGNOSTIC TESTS



Because antibiotic resistance occurs as part of a natural process in which bacteria evolve, it can be slowed but not stopped. Therefore, we will always need new antibiotics to keep up with resistant bacteria as well as new diagnostic tests to track the development of resistance.

Contact Information



Nadyne Hagmeier, RN
nhagmeier@kfmc.org

Kansas Foundation for Medical Care, Inc
800 SW Jackson St, Ste 700
Topeka, KS 66612

P: 785.271.4174